Completed PHASE4 INTERVENTIONAL NCT00567385

Liquid Somatropin Formulation in Children With Growth Hormone Deficiency

An Open, Multi-centre Trial Evaluating Acceptance of the New Liquid Growth Hormone Formulation - Norditropin® SimpleXx® in Children With GH Deficiency

Sponsor: Novo Nordisk A/S

Conditions Growth Hormone Deficiency in Children Growth Hormone Disorder

Interventions somatropin

Updated 7 times since 2017 Last updated: Feb 27, 2017 Started: Mar 10, 2003 Primary completion: Mar 22, 2004 Completion: Mar 22, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Growth Hormone Deficiency in Children and Growth Hormone Disorder, this trial is completed. The trial is conducted by Novo Nordisk A/S and has accumulated 7 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Mar 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Mar 2017 [monthly]

Completed PHASE4

First recorded

Mar 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novo Nordisk A/S

Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Altunizade-Istanbul, Turkey (Türkiye)